Off-Label Use of Letermovir as Preemptive Anti-Cytomegalovirus Therapy in a Pediatric Allogeneic Peripheral Blood Stem Cell Transplant

References

• Stern L, Withers B, Avdic S, et al. Human cytomegalovirus latency and reactivation in allogeneic hematopoietic stem cell transplant recipients. Front Microbiol. 2019;10:1186. doi:10.3389/fmicb.2019.0118631191499
   PubMed Web of Science ®Google Scholar
• Ruell J, Barnes C, Mutton K, et al. Active CMV disease does not always correlate with viral load detection. Bone Marrow Transplant. 2007;40:55–61. doi:10.1038/sj.bmt.170567117468776
   PubMed Web of Science ®Google Scholar
• Ljungman P, de la Camara R, Robin C, et al.; on behalf of the 2017 European Conference on Infections in Leukaemia group. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19:e260–e272. doi:10.1016/S1473-3099(19)30107-031153807
   PubMed Web of Science ®Google Scholar
• El Helou G, Razonable RR. Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review. Infect Drug Resist. 2019;12:1481–1491. doi:10.2147/IDR.S18090831239725
   PubMed Web of Science ®Google Scholar
• Chemaly RF, Chou S, Einsele H, et al. Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials. Clin Infect Dis. 2019;68:1420–1426. doi:10.1093/cid/ciy69630137245
   PubMed Web of Science ®Google Scholar
• Phoompoung P, Ferreira VH, Tikkanen J, et al. Letermovir as salvage therapy for cytomegalovirus infection in transplant recipients. Transplantation. 2020;104:404–409. doi:10.1128/AAC.02337-1832000236
   PubMed Web of Science ®Google Scholar
• Chiereghin A, Potena L, Borgese L, et al. Monitoring of cytomegalovirus (CMV)-specific cell-mediated immunity in heart transplant recipients: clinical utility of the QuantiFERON-CMV assay for management of posttransplant CMV infection. J Clin Microbiol. 2018;56:e01040–17. doi:10.1128/JCM.01040-1729305542
   PubMed Web of Science ®Google Scholar
• Chiereghin A, Piccirilli G, Belotti T, et al. Clinical utility of measuring Epstein–Barr virus specific cell mediated immunity after HSCT in addition to virological monitoring: results from a prospective study. Med Microbiol Immunol. 2019;208:825–834. doi:10.1007/s00430-019-00629-231289930
   PubMed Web of Science ®Google Scholar
• Allice T, Busca A, Locatelli F, Falda M, Pittaluga F, Ghisetti V. Valganciclovir as preemptive therapy for cytomegalovirus infection post allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus. J Antimicrob Chemother. 2009;63:600–608. doi:10.1093/jac/dkn52119147520
   PubMed Web of Science ®Google Scholar
• Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev. 2010;23:689–712. doi:10.1128/CMR.00009-1020930070
   PubMed Web of Science ®Google Scholar
• Gentry BG, Bogner E, Drach JC. Targeting the terminase: an important step forward in the treatment and prophylaxis of human cytomegalovirus infections. Antiviral Res. 2019;161:116–124. doi:10.1016/j.antiviral.2018.11.00530472161
   PubMed Web of Science ®Google Scholar
• Cassaniti I, Colombo AA, Bernasconi P, et al. Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection. Am J Transplant. 2021:1–7. doi:10.1111/ajt.16450.
   Web of Science ®Google Scholar
• Styczynski J, van der Velden W, Fox CP, et al.; Sixth European Conference on Infections in Leukemia, a joint venture of the Infectious Diseases Working Party of the European Society of Blood and Marrow Transplantation (EBMT-IDWP), the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer (EORTC-IDG), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016;101:803–811. doi:10.3324/haematol.2016.14442827365460
   PubMed Web of Science ®Google Scholar
• Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433–2444. doi:10.1056/nejmoa170664029211658
   PubMed Web of Science ®Google Scholar
• Ljungman P, Schmitt M, Marty FM, et al. A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation. Clin Infect Dis. 2020;70:1525–1533. doi:10.1093/cid/ciz49031179485
   PubMed Web of Science ®Google Scholar
• Marty FM, Ljungman PT, Chemaly RF, et al. Outcomes of patients with detectable CMV DNA at randomization in the Phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation. Am J Transplant. 2020;20:1703–1711. doi:10.1111/ajt.1576431883426
   PubMed Web of Science ®Google Scholar
• Cherrier L, Nasar A, Goodlet KJ, Nailor MD, Tokman S, Chou S. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. Am J Transplant. 2018;18:3060–3064. doi:10.1111/ajt.1513530286286
   PubMed Web of Science ®Google Scholar
• Koepf US, Klehr HU, Eis-Huebinger AM, et al. Suppression of CMV infection with letermovir in a kidney transplant patient. Eur J Case Rep Intern Med. 2020;7:001622. doi:10.12890/2020_00162232665929
   PubMedGoogle Scholar
• Frietsch JJ, Michel D, Stamminger T, et al. In vivo emergence of UL56 C325Y cytomegalovirus resistance to letermovir in a patient with acute myeloid leukemia after hematopoietic cell transplantation. Mediterr J Hematol Infect Dis. 2019;11:e2019001. doi:10.4084/MJHID.2019.00130671207
   PubMed Web of Science ®Google Scholar
• Kaul DR, Stoelben S, Cober E, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant. 2011;11:1079–1084. doi:10.1111/j.1600-6143.2011.03530.x21521474
   PubMed Web of Science ®Google Scholar
• Kilgore JT, Becken B, Varga MG, et al. Use of letermovir for salvage therapy for resistant cytomegalovirus in a pediatric hematopoietic stem cell transplant recipient. J Pediatric Infect Dis Soc. 2020;9:486–489. doi:10.1093/jpids/piz05031362308
   PubMed Web of Science ®Google Scholar
• Turner N, Strand A, Grewal DS, et al. Use of letermovir as salvage therapy for drug-resistant cytomegalovirus retinitis. Antimicrob Agents Chemother. 2019;63:e02337–18. doi:10.1128/AAC.02337-1830642941
   PubMed Web of Science ®Google Scholar
• Lin A, Maloy M, Su Y, et al. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: real-world experience. Transpl Infect Dis. 2019;21:e13187. doi:10.1111/tid.1318731585500
   PubMed Web of Science ®Google Scholar
• Robin C, Thiebaut A, Alain S, et al. Letermovir for secondary prophylaxis of CMV infection and disease after allogeneic hematopoietic cell transplantation: results from the French compassionate program. Biol Blood Marrow Transplant. 2020;26(5):978–984. doi:10.1016/j.bbmt.2020.01.02732035273
   PubMed Web of Science ®Google Scholar
• Sousa H, Boutolleau D, Ribeiro J, et al. Cytomegalovirus infection in patients who underwent allogeneic hematopoietic stem cell transplantation in Portugal: a five-year retrospective review. Biol Blood Marrow Transplant. 2014;20:1958e1967. doi:10.1016/j.bbmt.2014.08.01025139217
   PubMed Web of Science ®Google Scholar
• Cantoni N, Hirsch HH, Khanna N, et al. Evidence for a bidirectional relationship between cytomegalovirus replication and acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2010;16:1309–1314. doi:10.1016/j.bbmt.2010.03.02020353832
   PubMed Web of Science ®Google Scholar
• Chiereghin A, Bertuzzi C, Piccirilli G, et al. Successful management of EBV-PTLD in allogeneic bone marrow transplant recipient by virological-immunological monitoring of EBV infection, prompt diagnosis and early treatment. Transpl Immunol. 2016;34:60–64. doi:10.1016/j.trim.2015.12.00226687013
   PubMed Web of Science ®Google Scholar
• Campos AB, Ribeiro J, Boutolleau D, Sousa H. Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art. Rev Med Virol. 2016;26:161–182. doi:10.1002/rmv.187326990717
   PubMed Web of Science ®Google Scholar
• Göhring K, Hamprecht K, Jahn G. Antiviral drug- and multidrug resistance in cytomegalovirus infected SCT patients. Comput Struct Biotechnol J. 2015;13:153–159. doi:10.1016/j.csbj.2015.01.00325750703
   PubMed Web of Science ®Google Scholar
• Ciorba A, Corazzi V, Conz V, Bianchini C, Aimoni C. Facial nerve paralysis in children. World J Clin Cases. 2015;3:973–979. doi:10.12998/wjcc.v3.i12.97326677445
   PubMed Web of Science ®Google Scholar
• Hakki M. Moving past ganciclovir and foscarnet: advances in CMV therapy. Curr Hematol Malig Rep. 2020;15:90–102. doi:10.1007/s11899-020-00557-631981100
   PubMed Web of Science ®Google Scholar